FindTrial
Sign In

Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor

DRUG5 trials

Sponsors

Aswan University, Clinical Research Centre, Malaysia, Vanderbilt University Medical Center, Assiut University, Josip Juraj Strossmayer University of Osijek

Conditions

Atrial FibrillationCoronary Artery DiseaseDiabetes Mellitus, Type 2Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)Healthy VolunteerMODY2 DiabetesNon-Alcoholic Fatty Liver DiseaseSGLT 2 Inhibitors

Early Phase 1

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
RecruitingNCT06609356
Vanderbilt University Medical CenterGlucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), Healthy Volunteer, MODY2 Diabetes +1
Start: 2025-07-03End: 2027-12-31Target: 27Updated: 2025-12-23

Unknown Phase

Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling
CompletedNCT05993897
Aswan UniversityAtrial Fibrillation
Start: 2024-08-20End: 2025-10-15Updated: 2026-07-13
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)
NCT06128096
Clinical Research Centre, MalaysiaCoronary Artery Disease
Start: 2022-06-01End: 2024-12-31Target: 360Updated: 2023-11-24
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients
Not yet recruitingNCT07186153
Assiut UniversitySGLT 2 Inhibitors
Start: 2025-10-01End: 2026-11-01Target: 100Updated: 2025-09-22
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
CompletedNCT07269197
Josip Juraj Strossmayer University of OsijekDiabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
Start: 2024-03-22End: 2025-10-10Updated: 2025-12-08